A 28-year-old agricultural worker is admitted with organophosphate poisoning. After receiving atropine 15 mg IV over 20 minutes with good response (pupils dilated, secretions dried, HR 72 bpm), he remains weak with persistent muscle fasciculations and inability to lift his head off the pillow. Respiratory rate is 26/min and SpO₂ is 94% on room air. What is the most appropriate next step?

Explanation

## Clinical Scenario Analysis This patient has achieved **muscarinic control** (atropine response evident: dilated pupils, dry mouth, normal heart rate). However, he has **persistent nicotinic effects**: muscle weakness, fasciculations, and respiratory muscle involvement (tachypnea, borderline SpO₂). This is the ideal moment to introduce pralidoxime. ## Pralidoxime: Timing and Role **Key Point:** Pralidoxime (2-PAM) is an oxime that reactivates acetylcholinesterase by removing the phosphoryl group from the enzyme. It is most effective when given *early* (ideally within 24–48 hours, but especially within the first 6–12 hours) before "aging" of the enzyme-inhibitor complex occurs. ### Why Pralidoxime Now? 1. **Nicotinic effects persist** — Muscle weakness and fasciculations indicate ongoing acetylcholine excess at the neuromuscular junction. 2. **Atropine cannot help** — Atropine only blocks muscarinic receptors; it does not restore acetylcholinesterase function. 3. **Time window is critical** — Pralidoxime works best in the first 24–48 hours. Delaying increases the risk of enzyme "aging," after which the drug becomes ineffective. 4. **Respiratory compromise** — Tachypnea and borderline SpO₂ suggest respiratory muscle weakness; pralidoxime will improve neuromuscular transmission and reduce intubation risk. ## Dosing and Administration | Parameter | Details | | --- | --- | | **Loading dose** | 1 g IV bolus over 5–10 minutes | | **Repeat dosing** | 1 g IV every 4–6 hours if muscle weakness persists | | **Maximum daily dose** | 12 g (in severe cases) | | **Onset** | 30–40 minutes | | **Duration** | 4–6 hours | **High-Yield:** Pralidoxime must be given *alongside* atropine (which is continued), not instead of it. The combination addresses both muscarinic and nicotinic effects. **Clinical Pearl:** If the patient deteriorates despite pralidoxime (worsening respiratory weakness, inability to protect airway), intubation becomes necessary. But starting pralidoxime now may prevent intubation altogether by restoring neuromuscular function.